drugset / Trial / NCT00398307

Evaluating Patients With Varying Degrees of Renal Function

NCT00398307

Phase 1 Completed 24 enrolled Taiho Oncology, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase I, open-label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of renal function. Patients will be stratified by baseline 24-hour creatinine clearance(CrCL) into 4 cohorts using the normal clearance formula: Group A: Control Group B:Mild renal dysfunction Group C:Moderate renal function and Group D: Severe renal dysfunction. Six patients will be enrolled into each cohort.

Timeline

Start
2006-02
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject S-1 Small molecule 20 mg/m2 Oral
Subject S-1 Small molecule 30 mg/m2 Oral
Background Cisplatin Other / unclassified